Brahm Coler1, Tsung-Yen Wu2, Lindsey Carlson3, Nicole Burd2, Jeff Munson4, Matthew Dacanay2, Orlando Cervantes5, Sean Esplin6, Raj P Kapur7, Helen Feltovich8, Kristina M Adams Waldorf9. 1. Elson S. Floyd College of Medicine, Washington State University, Spokane, WA; Department of Obstetrics and Gynecology, University of Washington, Seattle, WA. 2. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA. 3. Women and Newborn Research, Intermountain Health Care, Salt Lake City, UT. 4. Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA. 5. Department of Global Health, University of Washington, Seattle, WA. 6. Department of Obstetrics and Gynecology, Intermountain Health Care, Salt Lake City, UT. 7. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA; Department of Pathology, Seattle Children's Hospital, Seattle, WA. 8. Department of Obstetrics and Gynecology, Intermountain Health Care, Salt Lake City, UT. Electronic address: hfeltovich@gmail.com. 9. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA; Department of Global Health, University of Washington, Seattle, WA. Electronic address: adamsk@uw.edu.
Abstract
BACKGROUND: COVID-19 is caused by the SARS-CoV-2 virus and is associated with critical illness requiring hospitalization, maternal mortality, stillbirth, and preterm birth. SARS-CoV-2 has been shown to induce placental pathology. However, substantial gaps exist in our understanding of the pathophysiology of COVID-19 disease in pregnancy and the long-term impact of SARS-CoV-2 on the placenta and fetus. To what extent a SARS-CoV-2 infection of the placenta alters the placental antiviral innate immune response is not well understood. A dysregulated innate immune response in the setting of maternal COVID-19 disease may increase the risk of inflammatory tissue injury or placental compromise and may contribute to deleterious pregnancy outcomes. OBJECTIVE: We sought to determine the impact of a maternal SARS-CoV-2 infection on placental immune response by evaluating gene expression of a panel of 6 antiviral innate immune mediators that act as biomarkers of the antiviral and interferon cytokine response. Our hypothesis was that a SARS-CoV-2 infection during pregnancy would result in an up-regulated placental antiviral innate immune response. STUDY DESIGN: We performed a case-control study on placental tissues (chorionic villous tissues and chorioamniotic membrane) collected from pregnant patients with (N=140) and without (N=24) COVID-19 disease. We performed real-time quantitative polymerase chain reaction and immunohistochemistry, and the placental histopathology was evaluated. Clinical data were abstracted. Fisher exact test, Pearson correlations, and linear regression models were used to examine proportions and continuous data between patients with active (<10 days since diagnosis) vs recovered COVID-19 (>10 days since diagnosis) at the time of delivery. Secondary regression models adjusted for labor status as a covariate and evaluated potential correlation between placental innate immune gene expression and other variables. RESULTS: SARS-CoV-2 viral RNA was detected in placental tissues from 5 women with COVID-19 and from no controls (0/24, 0%). Only 1 of 5 cases with detectable SARS-CoV-2 viral RNA in placental tissues was confirmed to express SARS-CoV-2 nucleocapsid and spike proteins in syncytiotrophoblast cells. We detected a considerably lower gene expression of 5 critical innate immune mediators (IFNB, IFIT1, MXA, IL6, IL1B) in the chorionic villi and chorioamniotic membranes from women with active or recovered COVID-19 than controls, which remained significant after adjustment for labor status. There were minimal correlations between placental gene expression and other studied variables including gestational age at diagnosis, time interval between COVID-19 diagnosis and delivery, prepregnancy body mass index, COVID-19 disease severity, or placental pathology. CONCLUSION: A maternal SARS-CoV-2 infection was associated with an impaired placental innate immune response in chorionic villous tissues and chorioamniotic membranes that was not correlated with gestational age at COVID-19 diagnosis, time interval from COVID-19 diagnosis to delivery, maternal obesity, disease severity, or placental pathology.
BACKGROUND: COVID-19 is caused by the SARS-CoV-2 virus and is associated with critical illness requiring hospitalization, maternal mortality, stillbirth, and preterm birth. SARS-CoV-2 has been shown to induce placental pathology. However, substantial gaps exist in our understanding of the pathophysiology of COVID-19 disease in pregnancy and the long-term impact of SARS-CoV-2 on the placenta and fetus. To what extent a SARS-CoV-2 infection of the placenta alters the placental antiviral innate immune response is not well understood. A dysregulated innate immune response in the setting of maternal COVID-19 disease may increase the risk of inflammatory tissue injury or placental compromise and may contribute to deleterious pregnancy outcomes. OBJECTIVE: We sought to determine the impact of a maternal SARS-CoV-2 infection on placental immune response by evaluating gene expression of a panel of 6 antiviral innate immune mediators that act as biomarkers of the antiviral and interferon cytokine response. Our hypothesis was that a SARS-CoV-2 infection during pregnancy would result in an up-regulated placental antiviral innate immune response. STUDY DESIGN: We performed a case-control study on placental tissues (chorionic villous tissues and chorioamniotic membrane) collected from pregnant patients with (N=140) and without (N=24) COVID-19 disease. We performed real-time quantitative polymerase chain reaction and immunohistochemistry, and the placental histopathology was evaluated. Clinical data were abstracted. Fisher exact test, Pearson correlations, and linear regression models were used to examine proportions and continuous data between patients with active (<10 days since diagnosis) vs recovered COVID-19 (>10 days since diagnosis) at the time of delivery. Secondary regression models adjusted for labor status as a covariate and evaluated potential correlation between placental innate immune gene expression and other variables. RESULTS: SARS-CoV-2 viral RNA was detected in placental tissues from 5 women with COVID-19 and from no controls (0/24, 0%). Only 1 of 5 cases with detectable SARS-CoV-2 viral RNA in placental tissues was confirmed to express SARS-CoV-2 nucleocapsid and spike proteins in syncytiotrophoblast cells. We detected a considerably lower gene expression of 5 critical innate immune mediators (IFNB, IFIT1, MXA, IL6, IL1B) in the chorionic villi and chorioamniotic membranes from women with active or recovered COVID-19 than controls, which remained significant after adjustment for labor status. There were minimal correlations between placental gene expression and other studied variables including gestational age at diagnosis, time interval between COVID-19 diagnosis and delivery, prepregnancy body mass index, COVID-19 disease severity, or placental pathology. CONCLUSION: A maternal SARS-CoV-2 infection was associated with an impaired placental innate immune response in chorionic villous tissues and chorioamniotic membranes that was not correlated with gestational age at COVID-19 diagnosis, time interval from COVID-19 diagnosis to delivery, maternal obesity, disease severity, or placental pathology.
Authors: Ricardo A Machón; Matti O Huttunen; Sarnoff A Mednick; Juhani Sinivuo; Antti Tanskanen; Jennifer Bunn Watson; Markus Henriksson; Reijo Pyhälä Journal: Schizophr Res Date: 2002-03-01 Impact factor: 4.939
Authors: R J Martinez-Portilla; A Sotiriadis; C Chatzakis; J Torres-Torres; S Espino Y Sosa; K Sandoval-Mandujano; D A Castro-Bernabe; V Medina-Jimenez; J C Monarrez-Martin; F Figueras; L C Poon Journal: Ultrasound Obstet Gynecol Date: 2020-12-15 Impact factor: 7.299
Authors: Torri D Metz; Rebecca G Clifton; Brenna L Hughes; Grecio J Sandoval; William A Grobman; George R Saade; Tracy A Manuck; Monica Longo; Amber Sowles; Kelly Clark; Hyagriv N Simhan; Dwight J Rouse; Hector Mendez-Figueroa; Cynthia Gyamfi-Bannerman; Jennifer L Bailit; Maged M Costantine; Harish M Sehdev; Alan T N Tita; George A Macones Journal: JAMA Date: 2022-02-22 Impact factor: 157.335
Authors: M A Beesley; J R Davidson; F Panariello; S Shibuya; D Scaglioni; B C Jones; K Maksym; O Ogunbiyi; N J Sebire; D Cacchiarelli; A L David; P De Coppi; Mfm Gerli Journal: BJOG Date: 2021-11-18 Impact factor: 7.331
Authors: Laura D Zambrano; Sascha Ellington; Penelope Strid; Romeo R Galang; Titilope Oduyebo; Van T Tong; Kate R Woodworth; John F Nahabedian; Eduardo Azziz-Baumgartner; Suzanne M Gilboa; Dana Meaney-Delman Journal: MMWR Morb Mortal Wkly Rep Date: 2020-11-06 Impact factor: 17.586